Fig. 3

Publication and citation growth. The number of annual publications (column a, c, e, g) and the number of annual citations (column b, d, f, h) for a, b 3 PCSK9 inhibitors (alirocumab, evolocumab, and bococizumab), c, d 3 PDE5 inhibitors (vardenafil, tadalafil, and sildenafil), e, f 8 HMG-CoA reductase inhibitors (cerivastatin, pitavastatin, fluvastatin, lovastatin, rosuvastatin, pravastatin, simvastatin, and atorvastatin,), and g, h 5 TNF inhibitors (certolizumab pegol, golimumab, etanercept, adalimumab, and Infliximab). In total, 170,099,684 publications dating from 1900 to 2017 were analyzed (see the “Methods” section)